ClinicalTrials.gg
Not yet recruitingNCT07836010Updated Sep 23, 2026

Suzetrigine Added to Multimodal Analgesia for Women Undergoing Minimally Invasive Hysterectomy

A Phase 4 interventional study of Suzetrigine in Postoperative Pain, sponsored by Duke University. Not yet recruiting. Open to female participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-09-23.

Sponsored by Duke University · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
123
Allocation
Non-randomized
Ages
18 Years to 90 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing suzetrigine in Pain, Postoperative — 17 open to participants now, 17 under way, 4 of them phase 3. suzetrigine · Pain, Postoperative.

Planned enrollment
7th of 18
123 · median 115
Started
2026
with 14 others
Phase 4
14 of 18
13 open now
Primary completion
2028-01
later than 12 of 16 live
Registered
15th of 18
by date
Lead sponsor
1 of 18
Duke University

Among the 18 studies testing suzetrigine in Pain, Postoperative, this one is the 7th largest by planned enrollment, is one of 15 that started in 2026, is one of 14 in phase 4, reaches primary completion later than 12 of the 16 other live ones, and was the 15th registered.

Pain, Postoperative

5,648 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

17 of the 18 studies testing suzetrigine in Pain, Postoperative are open now, in 1 country. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 17 open studies →

Where they have run

About suzetrigine

suzetrigine: first FDA approval 2025 (JOURNAVX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 18 Years to 90 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing suzetrigine in Pain, Postoperative, or all of them as a file.
02

Study summary

This study will assess the analgesic efficacy of suzetrigine as part of a multimodal analgesic regimen in women undergoing laparoscopic or robotic hysterectomy. Outcomes will be compared with matched historical controls receiving the current ERAS regimen without suzetrigine.

Read the detailed description

This will be a matched cohort study with a prospective and a retrospective component. Women undergoing laparoscopic/robotic hysterectomy with our ERAS protocol will be approached to participate in the prospective open label component of the study. In the preoperative holding area, patients will be asked about their preoperative anxiety and expectations for postoperative pain. Preoperative patient-reported anxiety will be assessed by asking the question: "On a scale from 1 to 100, how anxious are you regarding your upcoming surgery?" Postoperative anticipated opioid need will be measured by asking, "Do you anticipate requiring below average, average, or above average amount of pain medication following surgery?". Preoperatively, patients will receive the first dose of suzetrigine (100 mg) approximately 1 hour prior to surgery. Midazolam can be used for anxiolysis as needed. Intraoperatively, patients will receive the usual intraoperative ERAS analgesic regimen used at Duke university typically incorporating intraoperative opioids (typically fentanyl and hydromorphone), intraoperative IV acetaminophen 1000 mg and IV ketorolac 15 mg. In PACU, IV fentanyl will be allowed for analgesia as per standard practice. Postoperative multimodal analgesia will incorporate scheduled acetaminophen, ibuprofen and suzetrigine (50 mg q12h, oral) around the clock. Oral oxycodone will be used for rescue as required. Patients will be encouraged to wait at least 60 minutes after taking a dose of acetaminophen and ibuprofen before use of the opioid rescue. Patients will be contacted daily to collect data about verbal rating pain scores (0= no pain, 10= worst possible pain), opioid consumption and any adverse events. In addition, on day 7, additional information will be collected about patient global assessment of pain control (poor, fair, good, very good, excellent).

Cases will be matched in a 1:2 ratio by age, race, insurance status, duration of surgery, preoperative anxiety and anticipated need for analgesia with historical controls who received postoperative analgesia using our current multimodal analgesic regimen. The historical controls will be identified from a database of patients who underwent minimally invasive hysterectomy with documented end points that the investigators are using in this study. Those patients also have information documented that was collected prospectively about anxiety and anticipated analgesic needs, factors that have been shown to be associated with postoperative opioid consumption.

03

Conditions studied

  • Postoperative Pain

Browse trials for

Keywords

  • Suzetrigine
  • Hysterectomy
  • Multimodal Analgesia
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients ≥18 years presenting for a laparoscopic/robotic hysterectomy.
  • ASA Classification I-III.

Exclusion criteria

Exclusion Criteria:

  • Chronic pain or chronic opioid therapy.
  • Allergy or to any component of the multimodal analgesic regimen.
  • Need to convert to an open procedure.
  • Subjects with severe hepatic or renal impairment and those receiving inhibitors.
  • Inability to communicate pain scores or need for analgesics.
  • Suspected or known addiction to or abuse of illicit drugs, prescription medicine(s) or alcohol within the past 2 years.
  • Psychiatric disorders that, in the opinion of the investigator, may interfere with study assessments or compliance.
  • Current or historical evidence of any disease or condition that, in the opinion of the investigator, may increase the risk of surgery or complicate the subject's postoperative course.
  • Pregnancy.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
123 participants (estimated)

Study arms

  • Experimental
    Suzetrigine Group

    Suzetrigine added to standard multimodal analgesia

    Drug: Suzetrigine

  • No intervention
    Control Group

    Standard Multimodal analgesia (historical cohort)

Interventions

  • Suzetrigine is an oral non-opioid pain medication used to treat moderate-to-severe acute pain in adults.

    Also known as: Journavx

06

What researchers measure

Primary outcomes

  1. Postoperative opioid use after Post-Anesthesia Care Unit (PACU) discharge following surgery

    Number of participants needing any opioids

    Time frame: Up to 7 days after PACU discharge following surgery

Secondary outcomes

  1. Total post-surgical opioid consumption after PACU discharge following surgery

    Total opioid consumption in mg

    Time frame: Up to 7 days after PACU discharge following surgery

  2. Average pain score in the first week following PACU discharge after surgery

    Average verbal rating pain score

    Time frame: Up to 7 days after PACU discharge following surgery

  3. Pain score on day 7

    Verbal rating pain score (0=no pain, 10= worst possible pain)

    Time frame: Day 7 after surgery

  4. Duration of PACU stay

    Minutes of stay in PACU

    Time frame: PACU stay, up to approximately 3 hours

  5. Need for opioids in PACU

    Number of participants needing any opioids in PACU

    Time frame: PACU stay, up to approximately 3 hours

  6. Opioid consumption in PACU

    Total opioid consumption in mg morphine equivalents

    Time frame: PACU stay, up to approximately 3 hours

Other outcomes

  1. Opioid related side effects in the suzetrigine group

    Number of participants with nausea, vomiting, itching, constipation and ileus

    Time frame: Up to 7 days after PACU discharge following surgery

  2. Proportion of participants reporting good, very good, or excellent on a Patient Global Assessment (PGA) for pain control at 7 days after surgery.

    Number of patients reporting good, very good, or excellent on a Patient Global Assessment (PGA) for pain control at 7 days after surgery (scale includes the following responses: poor, fair, good, very good, excellent).

    Time frame: Day 7 after surgery

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Jan 2028, 14 months later.

Of 532 non-industry phase 4 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's planned 14 months is below that.

Counting every sponsor, half of 542 studies reached it within 16 months; a quarter within 8 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2026
First posted
Sep 23, 2026
StartEst.
Nov 2026
Primary completionEst.
Jan 2028
CompletionEst.
Feb 2028
Last update
Sep 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07836010
Lead sponsor
Duke University
Responsible party
Sponsor
First posted
Sep 23, 2026
Start date
Nov 2026 (estimated)
Primary completion
Jan 2028 (estimated)
Completion
Feb 2028 (estimated)
Last update
Sep 23, 2026

Study contacts

Ashraf Habib
principal investigator · Duke University

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Suzetrigine

Start the discussion